Literature DB >> 32814856

Contribution of iron status at birth to infant iron status at 9 months: data from a prospective maternal-infant birth cohort in China.

Jie Shao1,2, Blair Richards3, Niko Kaciroti3, Bingquan Zhu4, Katy M Clark3, Betsy Lozoff3,5.   

Abstract

BACKGROUND/
OBJECTIVES: The contribution of iron status at birth to iron status in infancy is not known. We used a physiologic framework to evaluate how iron status at birth related to iron status at 9 months, taking iron needs and sources into account. SUBJECTS/
METHODS: In a longitudinal birth cohort in China, iron status measures in cord blood and venous blood in infancy (9 months) and clinical data were prospectively collected in 545 healthy term maternal-infant dyads. We used structural equation modeling (SEM) to create a 9-month iron composite and to assess direct and indirect contributions of multiple influences on 9-month iron status. Logistic regression was used to calculate odds ratios for iron deficiency (ID), iron deficiency anemia (IDA), and anemia.
RESULTS: Approximately 15% (78/523) of infants were born with cord SF <75 µg/l, suggesting fetal-neonatal ID. At 9 months, 34.8% (186/535) and 19.6% (105/535) of infants had ID and IDA, respectively. The following factors were independently associated with poorer 9-month iron status: higher cord zinc protoporphyrin/heme (ZPP/H) (adjusted estimate -0.18, P < 0.001) and serum transferrin receptor (sTfR) (-0.11, P = 0.004), lower cord hemoglobin (Hb) (0.13, P = 0.004), lower birth weight (0.15, P < 0.001), male sex (0.10, P = 0.013), older age at testing (-0.26, P < 0.001), higher 9-month weight (-0.12, P = 0.006) and breastfeeding (0.38, P < 0.001). Breastfeeding at 9 months showed the strongest association, adjusting for all other factors. Compared to formula-fed infants, the odds of IDA were 19.1 (95% CI: 6.92, 52.49, P < 0.001) and 3.6 (95% CI: 1.04, 12.50, P = 0.043) times higher in breastfed and mixed-fed infants, respectively.
CONCLUSIONS: Indicators of iron status at birth, postnatal iron needs, and iron sources independently related to iron status at 9 months. Sex was an additional factor. Public health policies to identify and protect infants at increased risk of ID should be prioritized.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32814856      PMCID: PMC7878278          DOI: 10.1038/s41430-020-00705-4

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  3 in total

1.  The clinical measurement of serum transferrin receptor.

Authors:  C H Flowers; B S Skikne; A M Covell; J D Cook
Journal:  J Lab Clin Med       Date:  1989-10

2.  Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency.

Authors:  R L Rettmer; T H Carlson; M L Origenes; R M Jack; R F Labb
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

3.  Effectiveness of zinc protoporphyrin/heme ratio for screening iron deficiency in preschool-aged children.

Authors:  Kyeong Hee Yu
Journal:  Nutr Res Pract       Date:  2011-02-28       Impact factor: 1.926

  3 in total
  3 in total

1.  Association of Preconception Blood Pressure with the Risk of Anemia in Children under Five Years of Age: A Large Longitudinal Chinese Birth Cohort.

Authors:  Hang An; Huiting Chen; Zhiwen Li; Le Zhang; Yali Zhang; Jianmeng Liu; Rongwei Ye; Nan Li
Journal:  Nutrients       Date:  2022-06-26       Impact factor: 6.706

2.  Infantile Iron Deficiency Affects Brain Development in Monkeys Even After Treatment of Anemia.

Authors:  Roza M Vlasova; Qian Wang; Auriel Willette; Martin A Styner; Gabriele R Lubach; Pamela J Kling; Michael K Georgieff; Raghavendra B Rao; Christopher L Coe
Journal:  Front Hum Neurosci       Date:  2021-02-24       Impact factor: 3.169

3.  Zinc and iron adequacy and relative importance of zinc/iron storage and intakes among breastfed infants.

Authors:  Oraporn Dumrongwongsiri; Pattanee Winichagoon; Nalinee Chongviriyaphan; Umaporn Suthutvoravut; Veit Grote; Berthold Koletzko
Journal:  Matern Child Nutr       Date:  2021-09-08       Impact factor: 3.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.